Myomo Inc. · AMEX:MYO
Myomo — Investor Presentation (August 2023)
24 slides from Myomo's investor presentation, August 2023
Slide 1: Investor Presentation August 2023
INVESTOR PRESENTATION AUGUST 2023 Paul R. Gudonis, Chairman and CEO David Henry, CFO Conquering Upper Limb Paralysis with Wearable Medical Robotics NYSEAmerican: NYSE American: MYO MYO 1
Slide 2: Legal Disclaimer
Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials Legal Disclaimer This presentation contains forward-looking statements regarding the trading of the Company’s common stock on the NYSE American, the Company’s plans for the use of proceeds and
Slide 3: Investment Highlights: Market Leader in New Product Category
Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials Investment Highlights: Market Leader in New Product Category Ø Creating a new product category for this large unmet medical need - Patient Population with Chronic Arm Paralysis = Approx. 3M in
Slide 4: The Only Device to Enable a Paralyzed Arm to Move Again: My Own Motion
Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials THE ONLY DEVICE TO ENABLE A PARALYZED ARM TO MOVE AGAIN: MY OWN MOTION 4
Slide 5: Causes of Upper Extremity Paralysis
Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials Causes of Upper Extremity Paralysis Stroke TBI Major Dx Other Dx SCI Ø Stroke/CVA Ø Cerebral Palsy Ø Traumatic Brain BPI Ø Multiple Sclerosis Injury PI Ø ALS Ø Spinal Cord Injury Ø Spinal Muscu
Slide 6: Stroke, TBI, SCI patient video
Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials Stroke TBI SCI BPI PI https://youtu.be/vVrA9MownDQ 6
Slide 7: Defining the US Target Market
Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials Defining the US Target Market Prevalence Population Addressable Market (Chronic Arm Paralysis) New 6 - 12 mos. incidences: Rehab Therapy Stroke US: 800,000 Spinal Cord Injury Living Medically I
Slide 8: MyoPro Powered Arm Brace: How it Works
Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials MyoPro Powered Arm Brace: How it Works ➢ MyoPro uses advanced sensor technology as a brain-computer interface to detect the user’s intention to move via the body’s electromyogram (EMG) signal ➢
Slide 9: Enabling a Paralyzed Arm to Move Again
Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials Enabling a Paralyzed Arm to Move Again https://vimeo.com/781545268/da823e7df8?share=copy https://vimeo.com/781548558/76b59ad742?share=copy 9
Slide 10: Recent Clinical Research
Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials Recent Clinical Research Guidelines for Adult Stroke Rehabilitation and Recovery A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association “For in
Slide 11: New Clinical Research Submitted for Publication
Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials New Clinical Research Submitted for Publication Myoelectric Arm Orthosis Assists Functional Activities: A 3-Month Home Use Outcome Report Results: Statistically significant and clinically meani
Slide 12: Go-to-Market Approach: How a Patient Obtains a MyoPro
Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials Go-to-Market Approach: How a Patient Obtains a MyoPro Lead Generation Reimbursement MyoPro Custom Delivery & & Evaluation Approval Fabrication Payment New MyoPro 2+ Remote Measurement Referral
Slide 13: New: Added TV Advertising for Target Demographic
Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials New: Added TV Advertising for Target Demographic https://www.youtube.com/shorts/ym8FZLwW0qI 11
Slide 14: Go-to-Market Approach: Multi-Channel, Emphasis on Direct Billing and International Sales
Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials Go-to-Market Approach: Multi-Channel, Emphasis on Direct Billing and International Sales Q2 2023 Product Revenue % 4% Sales Channels: 12% 5% In-House Patient Delivery & Direct Billing 79% O&P P
Slide 15: International Update: Activity in Key Markets
Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials International Update: Activity in Key Markets New Rep added in UK Japan Patent Issued China JV company established - 19.9% Equity Interest for MYO shareholders China patents issued Launch of JV
Slide 16: Reimbursement Update
Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials Reimbursement Update HCPCS Codes L8701, L8702 for MyoPro Ø Issued January 2019 Senior Insured Population Ø Expanded Access for Medicare Advantage Beneficiaries 50% 50% Ø Case-by-Case Pre-Author
Slide 17: Reimbursement Update (Continued)
Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials Reimbursement Update (Continued) Military Ø Approved for Veterans Ø 70 VAMC’s have ordered MyoPro’s Medicare Part B – BIG NEWS! Ø CMS Proposed New Rule to Re-Classify the MyoPro in the Brace Ca
Slide 18: Reimbursement Status: International Markets
Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials Reimbursement Status: International Markets Germany: Reimbursement for the MyoPro is on a case-by-case basis, with insurance companies often paying for a six-month trial to demonstrate the bene
Slide 19: Key Milestones Driving Revenue Growth
Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials Key Milestones Driving Revenue Growth Revenues Record Int’l $M and VA Expanded # Revenue of Payers and VAMC’s 15.6 13.9 Pivot to Direct Billing, HCPCS Codes Higher ASP; Issued EU Launch 7.6 Com
Slide 20: Backlog and Pipeline are Leading Indicators of Revenue
Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials Backlog and Pipeline are Leading Indicators of Revenue 200 Backlog 1200 Pipeline 179 180 176 164 160 154 1000 140 131 120 800 969 100 600 80 60 53 761 400 40 20 200 0 3 3 19 20 21 22 0 02 02 20
Slide 21: P&L and Key Balance Sheet Metrics
Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials P&L and Key Balance Sheet Metrics P&L Key Balance Sheet Metrics Actual Actual Actual Actual Actual Actual ($000's) Q2'23 Q2'22 2022 2021 ($000's) Q2'23 Q1'23 Product Revenue $ 4,243 $ 3,677 $ 1
Slide 22: Drivers of Revenue Growth
Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials Drivers of Revenue Growth Increased Marketing in US and Germany Medicare Reimbursement New International Markets New Product Introduction for Continued Revenue Growth Introduce MyoPal for Pedia
Slide 23: Leadership Team & Board of Directors
Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials Leadership Team & Board of Directors Management Team Members Board of Directors Paul R. Gudonis Barry Camrell Thomas Kirk Chairman & CEO VP of QA/RA Lead Independent Scaled multiple tech co’s,
Slide 24: Thank You! For Additional Information
Thank You! For Additional Information: Paul R. Gudonis, CEO David Henry, CFO paul@myomo.com david.henry@myomo.com 617-401-2623 508-344-5235 24